Gilead upgraded by Morgan Stanley on lenacapavir potential
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. The investment bank said it was "leaning into the bull case," seeing "the potential for upward estimate revisions on lenacapavir for PrEP and further multiple expansion as the company makes progress with its
Bath & Body Works upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo upgraded Bath & Body Works to Overweight from Equal Weight with a price target of $48, up from $42. 2025 is set to be a “stock
ModivCare downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Raj Kumar downgraded ModivCare (MODV) to Equal Weight from Overweight with a price target of $17, down from $21, as coverage was transitioned to a new analyst. While recognizing the company’s “significant progress,
Morgan Stanley upgrades Gilead on HIV treatment growth
Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV treatments.
Gilead upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for
Hosted on MSN9h
Wells Fargo Initiates Coverage of Maplebear (CART) with Equal-Weight Recommendation
Fintel reports that on January 10, 2025, Wells Fargo initiated coverage of Maplebear (NasdaqGS:CART) with a Equal-Weight ...
NFTY: Keep The Faith In Equal-Weight India
Discover why India's recent mega-cap selloff presents an attractive entry point for investors, particularly with NFTY poised ...